Cieslewicz Brian, Makrinos Daniel, Burke Heidi, Bree Dara, Haridas Renuka, Tonkiss Ian, Bartsch Yannic, Alter Galit, Malley Richard, Besin Gilles
Affinivax, Cambridge, MA 02142, USA.
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Vaccines (Basel). 2022 Jul 3;10(7):1069. doi: 10.3390/vaccines10071069.
Despite the remarkable success of SARS-CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen-Presenting System (MAPS) technology, in which proteins are presented on a polysaccharide polymer to induce antibody, Th1, Th17 and CD8+ T cell responses, to engineer a novel vaccine targeting SARS-CoV-2. This vaccine contains a fragment of the spike (S) protein receptor-binding domain (RBD) sequence of the original D614G strain and was used to immunize nonhuman primates (NHP) for assessment of immunological responses and protection against SARS-CoV-2 challenge. The SARS-CoV-2 MAPS vaccine generated robust neutralizing antibodies as well as Th1, Th17 and cytotoxic CD8 T-cell responses in NHPs. Furthermore, MAPS-immunized NHPs had significantly lower viral loads in the nasopharynx and lung compared to control animals. Taken together, these findings support the use of the MAPS platform to make a SARS-CoV-2 vaccine. The nature of the platform also could enable its use for the inclusion of different variants in a single vaccine.
尽管SARS-CoV-2疫苗取得了显著成功，但变异毒株的出现，其中一些对疫苗效果更具抗性，凸显了对额外COVID-19疫苗的潜在需求。我们使用了多重抗原呈递系统（MAPS）技术，即蛋白质呈递在多糖聚合物上以诱导抗体、Th1、Th17和CD8+T细胞反应，来设计一种针对SARS-CoV-2的新型疫苗。这种疫苗包含原始D614G毒株刺突（S）蛋白受体结合域（RBD）序列的一个片段，并用于免疫非人类灵长类动物（NHP）以评估免疫反应和针对SARS-CoV-2攻击的保护作用。SARS-CoV-2 MAPS疫苗在NHP中产生了强大的中和抗体以及Th1、Th17和细胞毒性CD8 T细胞反应。此外，与对照动物相比，经MAPS免疫的NHP在鼻咽和肺部的病毒载量显著更低。综上所述，这些发现支持使用MAPS平台来制备SARS-CoV-2疫苗。该平台的特性还可能使其能够用于在单一疫苗中纳入不同的变异毒株。
